ABBV - Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments Strong Buy
2024-06-10 23:55:53 ET
Summary
- REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes.
- The company's pipeline includes promising candidates for age-related macular degeneration, Duchenne muscular dystrophy, and Hunter syndrome.
- ABBV-RGX-314, RGX-202, and RGX-121 are key pipeline candidates targeting significant markets with promising clinical data.
- The collaboration with AbbVie for ABBV-RGX-314 includes potential milestone payments and significant market potential in wet AMD and DR.
- I deem RGNX a "strong buy" due to its innovative pipeline, strategic partnerships, robust financial health, and potential market impact.
...
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy